Mar. 5 at 5:27 PM
Record Profits, a Vape Market Landgrab, and a CA
$250M Facility Bought for CA
$27M
https://ow.ly/twTw50YpLcg
Atrium Research initiated coverage on Cannara Biotech Inc. (
$LOVE.TO;
$LOVFF:OTCQX; BCB0:FSE), citing the company's dominant position in Quebec's new vape category, best-in-class EBITDA margins of 29%, and a capital-efficient expansion path at its Valleyfield facility that could unlock 100,000 kg of annual production capacity by FY30.